The company operates mostly on the over-the-counter drug and food supplements market, where its market share is 6% in value, Biofarm’s first half report says.
Total debt stood at RON92.5 million on June 30, slightly higher than the RON89.3 million at the end of last year, and assets stood at RON359.6 million, an increase of 3.74% on December 31, 2019.
Biofarm’s stock has seen a rise of 14.05% since the beginning of the year, amid a traded volume of RON7 milion, which led drove the company’s market capitalization to RON410 milion.
(English version by Loredana Fratila-Cristescu)